ROCK CREEK PHARMACEUTICALS INC COM STK (DE)
RCPI
RCPI was delisted on the 4th of November, 2015.
1 hedge funds and large institutions have $1 invested in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
80% less capital invested
Capital invested by funds: $5 → $1 (-$4)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$4 |
RCPI Hedge Fund Activity: Q2 2023 in Review
1 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) for Q2 2023, worth a combined $1 — down 80% from $5 a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of RCPI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Meeder Asset Management, exiting entirely with an estimated $4 sold.
- 1 institutional investor held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $1 of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) stock for Q2 2023, down 80% quarter-over-quarter.
- 0 funds opened new ROCK CREEK PHARMACEUTICALS INC COM STK (DE) positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest ROCK CREEK PHARMACEUTICALS INC COM STK (DE) seller in Q2 2023 was Meeder Asset Management, an estimated $4 sold.
Based on aggregated 13F filings for Q2 2023.